HAROLD C. NEU, M.D., F.A.C.P.; HERBERT SWARZ, M.D.
Carbenicillin, an alpha carboxybenzyl penicillin, was evaluated in the treatment of pseudomonas, proteus, and enterobacter infections in 41 patients. It was possible to obtain blood and urine concentrations of carbenicillin that were bactericidal for most Pseudomonas and Proteus strains by use of constant intravenous infusions of the drug. Carbenicillin was highly effective in the treatment of urinary tract infections and bacteremia. It was less effective in pulmonary infections, particularly in patients with advanced cystic fibrosis. Klebsiella overgrowth occurred in some patients treated for pulmonary and wound infections. Transient elevations of serum glutamic-oxalacetic transaminase (SGOT) were noted in children. Treatment with 30 g/day did not cause renal, hematologic, or neurologic toxicity. Carbenicillin represents a major advance in the therapy of serious pseudomonas and indole-positive proteus infections.
NEU HC, SWARZ H. Carbenicillin: Clinical and Laboratory Experience with a Parenterally Administered Penicillin for Treatment of Pseudomonas Infections. Ann Intern Med. ;71:903–911. doi: 10.7326/0003-4819-71-5-903
Download citation file:
Published: Ann Intern Med. 1969;71(5):903-911.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use